Listing of Claims:

1. (Currently amended) A method of treating a myelodysplastic syndrome, which comprises administering to a patient having myelodysplastic syndrome a therapeutically effective amount of cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 *H*-isoindol-4-yl}-amide, or a pharmaceutically acceptable salt~~, solvate~~, or stereoisomer thereof.

2. (Canceled)

3. (Previously presented) The method of claim 1 further comprising a therapeutically effective amount of at least one second active ingredient.

4. (Canceled)

5. (Previously presented) The method of claim 3, wherein the second active ingredient is capable of improving blood cell production.

6. (Previously presented) The method of claim 3, wherein the second active ingredient is a cytokine, hematopoietic growth factor, anti-cancer agent, antibiotic, proteasome inhibitor, or immunosuppressive agent.

7. (Previously presented) The method of claim 3, wherein the second active ingredient is etanercept, imatinib, anti-TNF-α antibodies, infliximab, G-CSF, GM-CSF, EPO, topotecan, pentoxifylline, ciprofloxacin, irinotecan, vinblastine, dexamethasone, IL2, IL8, IL18, Ara-C, vinorelbine, isotretinoin, 13-cis-retinoic acid, or a pharmacologically active mutant or derivative thereof.

8. (Previously presented) The method of claim 1 or 3, wherein the myelodysplastic syndrome is refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or chronic myelomonocytic leukemia.

9. (Previously presented) The method of claim 1 or 3, wherein the myelodysplastic syndrome is primary or secondary.

10-12. (Canceled)

13. (Previously presented) The method of claim 1 or 3, wherein the stereoisomer of cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 *H*-isoindol-4-yl}-amide is S enantiomer.

14. (Previously presented) The method of claim 1 or 3 wherein the stereoisomer of cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1 *H*-isoindol-4-yl}-amide is R enantiomer.

15-37. (Canceled)

38. (Currently amended) The method of claim 1, wherein the compound or a pharmaceutically acceptable salt~~, solvate~~ or stereoisomer thereof is administered before, during or after transplanting umbilical cord blood, placental blood, peripheral blood stem cell, hematopoietic stem cell preparation or bone marrow in the patient.

39. (Previously presented) The method of claim 3, wherein the second active ingredient is dexamethasone.

40. (Previously presented) The method of claim 1, wherein the patient has not been previously treated for a myelodysplastic syndrome.

41. (Previously presented) The method of claim 1, wherein the patient has been previously treated for a myelodysplastic syndrome.

42. (Currently amended) The method of claim 1, wherein the compound or a pharmaceutically acceptable salt~~, solvate~~ or stereoisomer thereof is administered orally.

43. (Currently amended) The method of claim 1, wherein the compound or a

pharmaceutically acceptable salt~~, solvate~~ or stereoisomer thereof is administered in the form of a capsule or tablet.

44. (Currently amended) The method of claim 1, wherein the compound or a pharmaceutically acceptable salt~~, solvate~~ or stereoisomer thereof is administered cyclically.

45. (Currently amended) The method of claim 44, wherein the compound or a pharmaceutically acceptable salt~~, solvate~~ or stereoisomer thereof is administered on days 1-21 every 28 days.

46. (Previously presented) The method of claim 44, wherein one cycle comprises the administration of the compound and at least one, two, or three weeks of rest.

47. (Previously presented) The method of claim 46, wherein the number of cycles is from one to twelve cycles.

48. (Currently amended) The method of claim 44, wherein the compound or a pharmaceutically acceptable salt~~, solvate~~ or stereoisomer thereof is administered in an amount of from about 10 mg to about 2500 mg per day on days 1-21 every 28 days.

49. (Currently amended) The method of claim 48, wherein the compound or a pharmaceutically acceptable salt~~, solvate~~ or stereoisomer thereof is administered in an amount of from about 100 mg to about 800 mg per day on days 1-21 every 28 days.

50. (Canceled).